GeoVax Labs (NASDAQ:GOVX) Trading Down 0.6% – Should You Sell?

Shares of GeoVax Labs Inc. (NASDAQ:GOVX) traded down 0.6% during trading on Wednesday . The company traded as low as $0.3911 and last traded at $0.3958. 370,379 shares changed hands during mid-day trading, a decline of 32% from the average session volume of 546,486 shares. The stock had previously closed at $0.3980.

Analysts Set New Price Targets

A number of analysts recently weighed in on the stock. Weiss Ratings reiterated a “sell (e+)” rating on shares of GeoVax Labs in a research report on Wednesday, October 8th. D. Boral Capital lowered their target price on shares of GeoVax Labs from $9.00 to $6.00 and set a “buy” rating for the company in a research note on Wednesday, November 19th. Three equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $7.50.

GeoVax Labs Stock Down 0.6%

The company has a market capitalization of $11.76 million, a P/E ratio of -0.28 and a beta of 3.64. The firm has a fifty day simple moving average of $0.50 and a 200-day simple moving average of $0.69.

GeoVax Labs (NASDAQ:GOVX) last released its quarterly earnings data on Thursday, November 13th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.24) by ($0.07). GeoVax Labs had a negative net margin of 403.88% and a negative return on equity of 489.67%. On average, sell-side analysts predict that GeoVax Labs Inc. will post -4.49 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GeoVax Labs

Several large investors have recently made changes to their positions in the stock. Jane Street Group LLC acquired a new stake in shares of GeoVax Labs during the first quarter worth $27,000. Armistice Capital LLC acquired a new position in GeoVax Labs in the 3rd quarter worth $253,000. Finally, Sabby Management LLC bought a new position in GeoVax Labs during the 3rd quarter worth about $313,000. Institutional investors own 6.09% of the company’s stock.

GeoVax Labs Company Profile

GeoVax Labs, Inc, a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and solid tumor cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers.